本帖最后由 老马 于 2013-3-13 13:43 编辑 7 H5 Z: }4 l. P- K' f
. h9 s9 F& ?2 d7 ]# b健择(吉西他滨)+顺铂+阿瓦斯汀# Q$ d" @8 x8 ~6 r7 l
Gemzar +Cisplatin + Avastin
9 q( d. @( U4 H0 z# zhttp://annonc.oxfordjournals.org/content/21/9/1804.full* e* C- Z& V4 {: W% U/ Q
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 0 U. Q, G: F/ E# _8 C! `' j
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
6 B+ k. S: \6 O3 R% E' ~Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
, C$ Q5 e% T0 H6 L; }( B
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 194)
7 h: }9 w: o4 `: m5 { R华为网盘附件:; M+ |/ v( T, }4 x5 O
【华为网盘】ava.JPG. l ^ R! V$ u5 i6 }3 ]
|